The most talked about health care story of the month was the potential mega deal between pharma heavyweights Pfizer (NYSE: PFE) and AstraZeneca (NYSE: AZN). The $118 billion inversion deal, would have moved Pfizer to the U.K. for a lower tax rate, gained it a potential immuno-oncology blockbuster drug, and set the combined company up to reduce costs while bulking up potential divisions for divestment.
However, none of that will come to pass. Pfizer, despite an aggressive courtship and PR effort that included testifying in front of the U.K. Parliament, couldn't convince AstraZeneca management of the deals merits. Pfizer's failure to close has left investors with more questions than answers.
In this video, Motley Fool health care analysts David Williamson and Michael Douglass discuss why this deal was important for Pfizer and potential next moves for the big pharma. Will Pfizer reload and go hunting for another big pharma or will it focus inward to create value for shareholders? Watch and find out.
David Williamson owns shares of Pfizer. Michael Douglass has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.